Sharp Therapeutics Corp. (TSXV:SHRX)
Canada flag Canada · Delayed Price · Currency is CAD
0.9100
-0.0900 (-9.00%)
At close: Jun 30, 2026

Sharp Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Cash & Equivalents
0.963.480.380.16
Cash & Short-Term Investments
0.963.480.380.16
Cash Growth
-72.55%824.64%129.45%-
Prepaid Expenses
0.060.030.050.03
Total Current Assets
1.023.520.430.2
Property, Plant & Equipment
0.921.021.11.21
Other Long-Term Assets
0.020.020.020.02
Total Assets
1.954.551.551.42

Liabilities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Accounts Payable
0.290.270.180.1
Accrued Expenses
0.550.250.230.13
Current Portion of Long-Term Debt
--7.283.94
Current Portion of Leases
0.110.040.030.03
Other Current Liabilities
-0.13--
Total Current Liabilities
0.950.697.724.2
Long-Term Debt
--3.973.8
Long-Term Leases
1.171.281.321.34
Other Long-Term Liabilities
--0.020.02
Total Liabilities
2.131.9713.039.37

Shareholders' Equity

Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Common Stock
2521.794.554.55
Additional Paid-In Capital
0.920.670.590.56
Retained Earnings
-26.06-19.89-16.62-13.06
Comprehensive Income & Other
-0.040.01--
Shareholders' Equity
-0.182.58-11.48-7.95
Total Liabilities & Equity
1.954.551.551.42

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Total Debt
1.281.3212.69.11
Net Cash (Debt)
-0.332.17-12.22-8.95
Net Cash Growth
----
Net Cash Per Share
-0.010.24-2.81-64.45
Filing Date Shares Outstanding
30.0829.940.140.14
Total Common Shares Outstanding
30.0828.220.140.14
Working Capital
0.062.83-7.29-4.01
Book Value Per Share
-0.010.09-82.45-57.25
Tangible Book Value
-0.182.58-11.48-7.95
Tangible Book Value Per Share
-0.010.09-82.45-57.25
Machinery
0.20.20.190.18
Leasehold Improvements
0.010.010.01-